NClip

Subcutaneous Medication Administration

4 min read

Subcutaneous Medication Administration

Key Points

  • Subcutaneous (SQ) injections deliver medication into fatty tissue for slower, sustained absorption.
  • Common sites include abdomen, upper arms, thighs, and buttocks; abdomen is often preferred.
  • Technique safety depends on aseptic preparation, correct needle selection, and angle/body-size matching.
  • Needle length should be individualized for tissue depth, including shorter choices in very thin/cachectic patients.
  • Some ordered SQ medications may be delivered via prefilled pen or auto-injector devices using product-specific activation steps.
  • SQ absorption can change with local blood-flow shifts (for example strenuous exercise or local heat/cold exposure at the site).
  • Typical SQ doses are often up to about 1 mL per injection in many adults; infants and small children commonly use smaller volumes (often up to about 0.5 mL) unless policy/order specifies otherwise.

Equipment

  • Ordered SQ medication and syringe
  • Needle typically 25G-31G and 3/8 to 5/8 in (9.5 to 15.9 mm), adjusted by age/body habitus and site
  • Needleless injector option when medication/device policy supports SQ administration
  • Antiseptic solution and gloves
  • Sharps container and documentation tools

Procedure Steps

  1. Verify patient identity, order, and medication rights before preparation.
  2. Assess suitability for SQ route, including tissue thickness, medication volume, and patient factors (including cachexia/thin habitus that may require shorter needle selection), and verify ordered volume aligns with site-specific tolerance.
  3. Select site (abdomen, upper arm, anterior thigh, upper ventral gluteal region, or upper back) and inspect skin integrity; for abdominal use, stay at least about 2 in (5 cm) from the umbilicus. Common subcutaneous injection sites across upper arm anterior thigh abdomen and upper buttock regions Illustration reference: OpenStax Fundamentals of Nursing Ch.11.3.
  4. Avoid sites that are bruised, scarred, open, over bony prominences, or affected by local infection/inflammation (for example cellulitis) or impaired tissue perfusion.
  5. Perform hand hygiene, apply nonsterile gloves, and if skin is visibly soiled cleanse with soap and water first; then prep with alcohol swab in a center-out circular motion (about 2 in/5 cm radius) for about 30 seconds and allow to dry.
  6. Prepare medication and pinch skin to create a skinfold.
  7. Insert needle with a quick, dart-like motion at a 45- to 90-degree angle based on tissue depth/body size; 90 degrees is common for normal/obese adults, and 45 degrees is commonly used when tissue is thin or skinfold depth is limited. Comparison of common injection angles by route (IM, SQ, IV, and ID) Illustration reference: OpenStax Clinical Nursing Skills Ch.12.
  8. Inject medication slowly (about 10 seconds per mL when tolerated); routine aspiration is not required for SQ injections.
  9. After completing medication delivery, hold the needle in place for about 10 seconds when indicated by product/protocol (for example many insulin-pen workflows) before withdrawal.
  10. Withdraw needle at the same angle used for insertion and apply gentle pressure with sterile gauze.
  11. Engage needle safety device immediately after injection (prefer hard-surface activation rather than finger activation when applicable), avoid recapping, and dispose needle and syringe in puncture-proof sharps container.
  12. Do not massage the site after injection.
  13. Document route, dose, site, and patient response/adverse reactions.
  14. Rotate sites systematically to reduce lipoatrophy and lipohypertrophy risk.

Medication-Specific Considerations

  • Heparin (SQ): high-alert medication requiring independent double-check of product, concentration, and dose; review coagulation parameters (for example PTT/aPTT per protocol), and for LMWH/heparin exposure follow platelet monitoring per policy for thrombocytopenia risk. Rotate injection sites, prefer abdominal tissue at least about 2 in (5 cm) from umbilicus, inject at 90 degrees over about 30 seconds, maintain skinfold when indicated, and do not massage after injection to reduce hematoma risk.
  • Insulin (SQ): high-alert medication requiring independent double-check of insulin type and dose before preparation and again before administration; use insulin syringes calibrated in units, verify product integrity (not expired and no unexpected discoloration/clumping), and time doses with meals/acting profile and current glucose results per policy. For insulin pens, use a new needle for each injection, prime per manufacturer guidance (commonly about 2 units), keep the pen in place about 10 seconds after injection, and never share pens between patients.
  • Age-site anchor (vaccine-focused SQ use): birth to 12 months commonly uses fatty tissue over the anterolateral thigh, while 12 months and older commonly uses fatty tissue over the triceps.

Common Errors

  • Poor site/angle selection → unreliable absorption and tissue trauma risk.
  • Breaks in aseptic technique → injection-site infection risk.
  • Rapid forceful injection → increased discomfort and local tissue injury.
  • Inadequate skin prep contact/dry time → contamination and local irritation risk.
  • Exceeding site-specific SQ volume tolerance → leakage, poor absorption, and injection-site pain risk.
  • Using bruised/tender/hard/swollen or bony-prominence sites → higher pain, tissue injury, and absorption variability risk.
  • Puncturing through a skin fold during insertion → accidental needlestick and technique failure risk.
  • Massaging site after SQ heparin → hematoma and bruising risk.
  • Incomplete site documentation → unsafe rotation and continuity gaps.

Graph View